REmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH. (READY-ICH)
5 juli 2026 uppdaterad av: Hong Yang, The Third Affiliated Hospital of Southern Medical University
Efficacy and Safety of an Early Intensive Blood Pressure-Lowering Strategy Using Remifentanil and Dexmedetomidine in Patients With Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Superiority, Randomized Controlled Trial
Intracerebral hemorrhage (ICH) remains the most devastating subtype of stroke, with a case fatality rate of approximately 40% at one months post-onset, imposing a particularly heavy medical and economic burden on low- and middle-income countries.
Studies have shown that poor prognosis in ICH patients is associated with acute blood pressure elevation and hematoma expansion after onset.
Blood pressure control during the acute phase is considered a potentially key therapeutic strategy for improving outcomes in ICH patients; however, no clinical study has yet demonstrated a clear advantage of any specific antihypertensive agent or combination.
Previous researchers have confirmed that the combined use of remifentanil and dexmedetomidine, while providing effective analgesia, sedation, and anti-sympathetic effects, could reduce dramatic fluctuations in blood pressure and heart rate, thereby facilitating more stable blood pressure reduction and potentially further improving functional outcomes in ICH patients.
The investigators plan to conduct a multicenter, prospective, randomized controlled, superiority clinical trial within mainland China to evaluate the efficacy and safety of an early intensive blood pressure-lowering strategy using remifentanil combined with dexmedetomidine for improving functional prognosis in acute ICH patients.
This study aims to provide evidence-based medical support for the use of remifentanil combined with dexmedetomidine in early intensive blood pressure-lowering in patients with ICH, to enrich the available options for early intensive blood pressure-lowering strategies, to improve the adverse prognosis of patients.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Spontaneous intracerebral hemorrhage refers to non-traumatic bleeding within the brain parenchyma caused by the rupture of large or small arteries, veins, or capillaries, which may secondarily extend into the ventricles or subarachnoid space. As one of the most devastating subtypes of stroke, intracerebral hemorrhage has a 30-day mortality rate of approximately 40%, with only 12-39% of patients regaining functional independence. Studies have shown that poor outcomes in intracerebral hemorrhage patients are closely associated with acute elevated blood pressure and hematoma expansion after onset, highlighting the urgent need to optimize clinical interventions. Therefore, understanding the pathophysiological mechanisms of acute blood pressure changes in intracerebral hemorrhage and refining early intensive antihypertensive strategies are of great clinical importance for improving patient outcomes. Previous researchers have demonstrated that a remifentanil and dexmedetomidine-based antihypertensive strategy enables rapid and stable blood pressure reduction. The investigators now intend to further investigate the efficacy and safety of this regimen compared to guideline-based standard treatment in improving patient outcomes.
This multi-center, prospective, open-label, randomized controlled, superiority clinical trial will be planned to be conducted in mainland China. It will primarily enroll patients with acute intracerebral hemorrhage who present within 6 hours of symptom onset and have an initial systolic blood pressure of 150 mmHg or higher. Patients will be excluded if they have contraindications to urgent intensive blood pressure-lowering therapy, if the hemorrhage is secondary to other etiologies, or if they have a high risk of death within 24 hours. Based on sample size calculation, a total of 1,116 patients with acute intracerebral hemorrhage will be enrolled and allocated in a 1:1 ratio to either the intervention group or the control group through randomization. Participants assigned to the control group will receive conventional treatment according to the "Guidelines for the Management of Spontaneous Intracerebral Hemorrhage" published by the American Heart Association and the American Stroke Association. Participants assigned to the intervention group will receive early intensive blood pressure-lowering therapy with remifentanil combined with dexmedetomidine, in addition to the guideline-based standard treatment. Specifically, remifentanil and dexmedetomidine will be administered as soon as possible within 30 minutes after enrollment. The primary outcome measure of this study is the modified Rankin Scale score at 90 days after treatment. Secondary outcome measures include blood pressure and blood glucose levels during the treatment period, the incidence of hematoma expansion, and the length of stay in the intensive care unit, among others. The results of this study are expected to fill the evidence gap regarding specific antihypertensive combinations in improving functional outcomes, and to provide high-quality evidence for future guideline updates.
Studietyp
Interventionell
Inskrivning (Beräknad)
1116
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Rui Dong, MM
- Telefonnummer: +86 -15622176026
- E-post: dongrui_0419@163.com
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years.
- Acute intracerebral hemorrhage confirmed by non-contrast head computed tomography.
- Symptom onset ≤ 6 h before randomization.
- At least two systolic blood pressure ≥ 150 mmHg separated by > 2 min prior to randomization.
- Admission to a monitored unit capable of active acute care (e.g., acute stroke unit, emergency department, or intensive care unit).
- Written informed consent provided by the patient or legally authorized representative.
Exclusion Criteria:
- Contraindication to intensive blood-pressure lowering (e.g., severe stenosis of carotid, vertebral, or cerebral arteries; Moyamoya disease; Takayasu arteritis; critical aortic stenosis).
- Clear evidence that the hemorrhage is secondary to a structural brain abnormality (arteriovenous malformation, aneurysm, tumor, trauma, infarct) or recent thrombolysis.
- Ischemic stroke within the preceding 30 days.
- Very high probability of death within 24 h based on clinical and/or radiologic criteria.
- Known advanced dementia or pre-stroke disability (pre- modified Rankin Scale score ≥ 3).
- Coagulopathy due to medication or hematologic disorder.
- Comorbid conditions that would interfere with outcome assessment or follow-up (e.g., active malignancy, end-stage organ failure).
- Known hypersensitivity to remifentanil or dexmedetomidine.
- Pregnancy or lactation.
- Concurrent participation in another investigational drug or device trial.
- Patient or legally authorized representative unwilling or unable to provide informed consent, or judged unlikely to comply with study procedures or follow-up.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Guideline-based standard care using remifentanil and dexmedetomidine
Based on the standard blood pressure treatment protocol from the 2022 American Heart Association/American Stroke Association "Guidelines for the Management of Spontaneous Intracerebral Hemorrhage," the administration of remifentanil and dexmedetomidine will be initiated within 1 hour after randomization.
The treatment will be continued for 7 days, or until the patient is transferred out of the intensive care unit if this occurs before day 7.
|
Participants will receive remifentanil and dexmedetomidine within 30 minutes after treatment initiation, and the treatment will be continued for 7 days or until discharge from the intensive care unit.
The starting dose of remifentanil is 0.025 μg/kg/min, which will be adjusted during infusion based on the patient's blood pressure and analgesic requirements.
For non-mechanically ventilated patients, the dose adjustment range is 0.025-0.05
μg/kg/min; for mechanically ventilated patients, the dose adjustment range is 0.025-0.15
μg/kg/min.
The starting dose of dexmedetomidine is 0.2 μg/kg/h, which will be adjusted during infusion based on the patient's blood pressure and sedation requirements, with a dose adjustment range of 0.2-0.7 μg/kg/h.
|
|
Aktiv komparator: Guideline-based standard care
Management will follow the 2022 American Heart Association/American Stroke Association "Guidelines for the Management of Patients with Spontaneous Intracerebral Hemorrhage".
|
Participants will receive conventional treatment in accordance with the "Guidelines for the Management of Spontaneous Intracerebral Hemorrhage" published by the American Heart Association and the American Stroke Association.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The modified Rankin Scale score at 90 days post-treatment
Tidsram: 90 days post-treatment
|
The modified Rankin Scale score at 90 days post-treatment will be analyzed as an ordinal outcome (scores 0-6).
The modified Rankin Scale is a standardized global 7-level disability scale, where a score of 0 or 1 indicates a favorable outcome (no symptoms or no significant disability), scores 2-5 represent increasing levels of disability and dependency, and a score of 6 indicates death.
|
90 days post-treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Poor Functional Outcome
Tidsram: 90 days post-treatment
|
A modified Rankin Scale score of 3-6 at 90 days is defined as a poor outcome, including death and severe disability.
Death is defined as modified Rankin Scale 6, and severe disability is defined as modified Rankin Scale 3-5.
Death and severe disability will be combined and reported as a composite poor outcome measure, and will also be analyzed separately.
|
90 days post-treatment
|
|
Blood Pressure Management
Tidsram: 24 hours, 3 days, and 7 days post-treatment
|
(1) 1-hour blood pressure control rate: Defined as at least twice systolic blood pressure measurements <140 mmHg within the first hour after treatment initiation.
(2) Mean blood pressure values: The average blood pressure values within 24 hours, 3 days, and 7 days post-treatment will be calculated for each group using all available measurements.
(3) Blood pressure variability: Coefficient of Variation and Average Real Variability will be calculated based on all blood pressure measurements obtained within 24 hours, 3 days, and 7 days post-treatment.
(4) Use of antihypertensive agents: The need for antihypertensive medications within 24 hours, 3 days, and 7 days post-treatment will be recorded.
Intravenous and oral/enteral medications will be documented separately, including the number of agents used if applicable.
|
24 hours, 3 days, and 7 days post-treatment
|
|
Glycemic Control
Tidsram: 24 hours, 3 days, and 7 days post-treatment
|
(1) Mean blood glucose values: The average glucose values within 24 hours, 3 days, and 7 days post-treatment will be calculated for each group using all available measurements.
(2) Hypoglycemia rate: Hypoglycemia is defined as a blood glucose level <2.8 mmol/L in non-diabetic patients and <4.0 mmol/L in diabetic patients.
The actual glucose value at the time of hypoglycemia will also be recorded.
(3) Insulin use: The need for insulin and the total insulin dosage within 24 hours, 3 days, and 7 days post-treatment will be documented.
|
24 hours, 3 days, and 7 days post-treatment
|
|
National Institutes of Health Stroke Scale
Tidsram: 7 days
|
National Institutes of Health Stroke Scale at 7 days will be evaluated.
|
7 days
|
|
Glasgow Coma Scale
Tidsram: 7 days
|
Glasgow Coma Scale at 7 days will be evaluated.
|
7 days
|
|
Hematoma Expansion
Tidsram: 24 hours and 7 days
|
Hematoma expansion is defined as an absolute increase in hematoma volume ≥12.5 mL or a relative increase >33% from baseline (V₁) to 24-hour of 7 days follow-up computed tomography (V₂), where V₁ is the baseline hematoma volume and V₂ is the volume at 24 hours and 7 days.
|
24 hours and 7 days
|
|
Quality of Life Assessment
Tidsram: 90 days
|
The EuroQol Five-Dimension Three-Level Questionnaire56 will be used to assess health-related quality of life at 90 days.
The EuroQol 5-dimension 3-level (EQ-5D-3L) patient-reported questionnaire covers 5 domains of health-related quality of life: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression.
Each domain has 3 graded levels of response: no problems, moderate, problems, or extreme problems.
Scores from these levels are combined to provide an overall health utility score that was calculated according to population norms in China.
A score of 1 represents perfect health, a score of 0 represents death, and negative scores represent health states considered to be worse than death.
|
90 days
|
|
Duration of Mechanical Ventilation
Tidsram: 7 days
|
For patients requiring mechanical ventilation, the start and end times of ventilation in the intensive care unit will be recorded, and the duration will be calculated in hours.
|
7 days
|
|
Intensive care unit Length of Stay
Tidsram: 7 days
|
The dates of intensive care unit admission and discharge will be recorded, and the length of stay will be calculated in days.
|
7 days
|
|
Hospitalization Status at 90 Days
Tidsram: 90 days
|
Whether the patient remains hospitalized at 90 days will be documented.
|
90 days
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Utredare
- Huvudutredare: Hong Yang, MD, The Third Affiliated Hospital of Southern Medical University
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001 Jul;33(5):337-43. doi: 10.3109/07853890109002087.
- Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin. 2009 Jul;25(3):451-69, vii. doi: 10.1016/j.ccc.2009.04.004.
- Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009 Apr;8(4):355-69. doi: 10.1016/S1474-4422(09)70025-0. Epub 2009 Feb 21.
- Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):660-7. doi: 10.1136/jnnp-2013-306476. Epub 2013 Nov 21.
- Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016 Sep 15;375(11):1033-43. doi: 10.1056/NEJMoa1603460. Epub 2016 Jun 8.
- Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 Jul;20(7):864-70. doi: 10.1161/01.str.20.7.864.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0. Epub 2010 Jan 5.
- GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3.
- Sykora M, Diedler J, Turcani P, Hacke W, Steiner T. Baroreflex: a new therapeutic target in human stroke? Stroke. 2009 Dec;40(12):e678-82. doi: 10.1161/STROKEAHA.109.565838. Epub 2009 Oct 15.
- Unchiti K, Leurcharusmee P, Samerchua A, Pipanmekaporn T, Chattipakorn N, Chattipakorn SC. The potential role of dexmedetomidine on neuroprotection and its possible mechanisms: Evidence from in vitro and in vivo studies. Eur J Neurosci. 2021 Nov;54(9):7006-7047. doi: 10.1111/ejn.15474. Epub 2021 Oct 25.
- Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013 Jun 20;368(25):2355-65. doi: 10.1056/NEJMoa1214609. Epub 2013 May 29.
- Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: A practical guide. Stat Med. 2020 Sep 20;39(21):2815-2842. doi: 10.1002/sim.8569. Epub 2020 May 17.
- Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A, Manios E, Konstantopoulou P, Mavrikakis M. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004 Feb;255(2):257-65. doi: 10.1046/j.1365-2796.2003.01291.x.
- Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available.
- Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Munoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25.
- Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol. 2014 Aug;13(8):844-54. doi: 10.1016/S1474-4422(14)70120-6.
- Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123.
- Society Of Critical Care Medicine Chinese Medical Association. [Guidelines for analgesia and sedation treatment in intensive care unit of Chinese adults]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 Jun;30(6):497-514. doi: 10.3760/cma.j.issn.2095-4352.2018.06.001. No abstract available. Chinese.
- Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014 Jul;17(5):597-604. doi: 10.1016/j.jval.2014.05.007. Epub 2014 Jul 23.
- Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011 Aug;42(8):2356-62. doi: 10.1161/STROKEAHA.111.619122. Epub 2011 Jun 30.
- Xiong J, Quan J, Qin C, Wang X, Dong Q, Zhang B. Remifentanil pretreatment attenuates brain nerve injury in response to cardiopulmonary bypass by blocking AKT/NRF2 signal pathway. Immunopharmacol Immunotoxicol. 2022 Aug;44(4):574-585. doi: 10.1080/08923973.2022.2069577. Epub 2022 Apr 29.
- Song HL, Zhang SB. Therapeutic effect of dexmedetomidine on intracerebral hemorrhage via regulating NLRP3. Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2612-2619. doi: 10.26355/eurrev_201903_17411.
- Huang J, Jiang Q. Dexmedetomidine Protects Against Neurological Dysfunction in a Mouse Intracerebral Hemorrhage Model by Inhibiting Mitochondrial Dysfunction-Derived Oxidative Stress. J Stroke Cerebrovasc Dis. 2019 May;28(5):1281-1289. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.016. Epub 2019 Feb 20.
- Liu H, Busl KM, Dore S. Role of Dexmedetomidine in Aneurysmal Subarachnoid Hemorrhage: A Comprehensive Scoping Review. J Neurosurg Anesthesiol. 2022 Apr 1;34(2):176-182. doi: 10.1097/ANA.0000000000000728.
- Tipps LB, Coplin WM, Murry KR, Rhoney DH. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery. 2000 Mar;46(3):596-601; discussion 601-2. doi: 10.1097/00006123-200003000-00015.
- Bischoff P, Plumer L, Scholz J, Drogemeier K, von Knobelsdorff G, Schulte am Esch J. [Effect of remifentanil on clinical and electroencephalographic parameters of depth of anesthesia in balanced anesthesia with propofol, enflurane or isoflurane]. Anaesthesiol Reanim. 1998;23(5):116-23. German.
- Ren C, Gao J, Xu GJ, Xu H, Liu G, Liu L, Zhang L, Cao JL, Zhang Z. The Nimodipine-Sparing Effect of Perioperative Dexmedetomidine Infusion During Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized, Controlled Trial. Front Pharmacol. 2019 Aug 2;10:858. doi: 10.3389/fphar.2019.00858. eCollection 2019.
- Tang CL, Li J, Zhang ZT, Zhao B, Wang SD, Zhang HM, Shi S, Zhang Y, Xia ZY. Neuroprotective effect of bispectral index-guided fast-track anesthesia using sevoflurane combined with dexmedetomidine for intracranial aneurysm embolization. Neural Regen Res. 2018 Feb;13(2):280-288. doi: 10.4103/1673-5374.226399.
- Potocnik I, Andjelkovic-Juvan L, Hostnik A, Markovic-Bozic J. Remifentanil target-controlled infusion with intranasal dexmedetomidine for vitreoretinal procedures: a randomized controlled trial. Croat Med J. 2021 Jun 30;62(3):233-240. doi: 10.3325/cmj.2021.62.233.
- Zeng XL, Liao JH, Zhong HS, Yin XH, Wang R, Liang JP, Zhang ZS. Meta-Analysis on the Anesthetic Effects of Remifentanil plus Dexmedetomidine versus Remifentanil Alone in Cardiac Surgery. Comput Math Methods Med. 2022 Sep 28;2022:1077980. doi: 10.1155/2022/1077980. eCollection 2022.
- Yi S, Cao H, Zheng W, Wang Y, Li P, Wang S, Zhou Z. Targeting the opioid remifentanil: Protective effects and molecular mechanisms against organ ischemia-reperfusion injury. Biomed Pharmacother. 2023 Nov;167:115472. doi: 10.1016/j.biopha.2023.115472. Epub 2023 Sep 15.
- Stroumpos C, Manolaraki M, Paspatis GA. Remifentanil, a different opioid: potential clinical applications and safety aspects. Expert Opin Drug Saf. 2010 Mar;9(2):355-64. doi: 10.1517/14740331003672579.
- Fodale V, Schifilliti D, Pratico C, Santamaria LB. Remifentanil and the brain. Acta Anaesthesiol Scand. 2008 Mar;52(3):319-26. doi: 10.1111/j.1399-6576.2007.01566.x.
- Pereon Y, Aubertin P, Guiheneuc P. Prognostic significance of electrophysiological investigations in stroke patients: somatosensory and motor evoked potentials and sympathetic skin response. Neurophysiol Clin. 1995;25(3):146-57. doi: 10.1016/0987-7053(96)80167-5.
- Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008 Jul 8;118(2):176-87. doi: 10.1161/CIRCULATIONAHA.107.723874. No abstract available.
- Gupta H, Beshara S, Katsanos A, Patil T, Al-Zahrani S, Chen JY, Alharbi A, Zamir N, Ng K, Kase CS, Shoamanesh A. Acute Hyperglycemia and In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage. Can J Neurol Sci. 2023 Jan;50(1):115-118. doi: 10.1017/cjn.2021.497. Epub 2021 Dec 6.
- Chen S, Wan Y, Guo H, Shen J, Li M, Xia Y, Zhang L, Sun Z, Chen X, Li G, He Q, Hu B. Diabetic and stress-induced hyperglycemia in spontaneous intracerebral hemorrhage: A multicenter prospective cohort (CHEERY) study. CNS Neurosci Ther. 2023 Apr;29(4):979-987. doi: 10.1111/cns.14033. Epub 2022 Nov 29.
- Wang X, Sandset EC, Moullaali TJ, Chen G, Song L, Carcel C, Delcourt C, Woodward M, Robinson T, Chalmers J, Arima H, Anderson CS; INTERACT2 Investigators. Determinants of the high admission blood pressure in mild-to-moderate acute intracerebral hemorrhage. J Hypertens. 2019 Jul;37(7):1463-1466. doi: 10.1097/HJH.0000000000002056.
- Hamann GF, Strittmatter M, Hoffmann KH, Holzer G, Stoll M, Keshevar T, Moili R, Wein K, Schimrigk K. Pattern of elevation of urine catecholamines in intracerebral haemorrhage. Acta Neurochir (Wien). 1995;132(1-3):42-7. doi: 10.1007/BF01404846.
- Leow MK, Loh KC, Kiat Kwek T, Ng PY. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common "pseudophaeochromocytoma". J Clin Pathol. 2007 May;60(5):583-4. doi: 10.1136/jcp.2006.036640. No abstract available.
- Takahashi H. Aldosterone, catecholamines, and CK-BB as biochemical markers in hypertensive intracerebral hemorrhage. Neurol Med Chir (Tokyo). 1989 Nov;29(11):999-1003. doi: 10.2176/nmc.29.999.
- Liang XM, Chen J, Zhang T, Liu J, Jiang XJ, Xu ZQ. Cerebral hemorrhage increases plasma concentrations of noradrenalin and creatine kinase MB fraction with induction of cardiomyocyte damage in rats. Cell Biochem Biophys. 2014 Dec;70(3):1807-11. doi: 10.1007/s12013-014-0133-z.
- Shoamanesh A, Patrice Lindsay M, Castellucci LA, Cayley A, Crowther M, de Wit K, English SW, Hoosein S, Huynh T, Kelly M, O'Kelly CJ, Teitelbaum J, Yip S, Dowlatshahi D, Smith EE, Foley N, Pikula A, Mountain A, Gubitz G, Gioia LC. Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020. Int J Stroke. 2021 Apr;16(3):321-341. doi: 10.1177/1747493020968424. Epub 2020 Nov 11.
- Mutimer CA, Yassi N, Wu TY. Blood Pressure Management in Intracerebral Haemorrhage: when, how much, and for how long? Curr Neurol Neurosci Rep. 2024 Jul;24(7):181-189. doi: 10.1007/s11910-024-01341-2. Epub 2024 May 23.
- Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gasecki D, Lal A, Manning LS, Sacco S, Steiner T, Tsivgoulis G. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021 Jun;6(2):II. doi: 10.1177/23969873211026998. Epub 2021 Jun 18.
- Cao Y, Yu S, Zhang Q, Yu T, Liu Y, Sun Z, Zhao M, Wang W, Zhao JZ; Chinese Stroke Association Stroke Council Guideline. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of intracerebral haemorrhage. Stroke Vasc Neurol. 2020 Dec;5(4):396-402. doi: 10.1136/svn-2020-000433. Epub 2020 Dec 1.
- Parry-Jones AR, Jarhult SJ, Kreitzer N, Morotti A, Toni D, Seiffge D, Mendelow AD, Patel H, Brouwers HB, Klijn CJ, Steiner T, Gibler WB, Goldstein JN. Acute care bundles should be used for patients with intracerebral haemorrhage: An expert consensus statement. Eur Stroke J. 2024 Jun;9(2):295-302. doi: 10.1177/23969873231220235. Epub 2023 Dec 27.
- Corrections. Lancet Neurol. 2018 Nov;17(11):933. doi: 10.1016/S1474-4422(18)30354-5. Epub 2018 Sep 19. No abstract available.
- Brouwers HB, Chang Y, Falcone GJ, Cai X, Ayres AM, Battey TW, Vashkevich A, McNamara KA, Valant V, Schwab K, Orzell SC, Bresette LM, Feske SK, Rost NS, Romero JM, Viswanathan A, Chou SH, Greenberg SM, Rosand J, Goldstein JN. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol. 2014 Feb;71(2):158-64. doi: 10.1001/jamaneurol.2013.5433.
- Dong R, Li F, Li B, Chen Q, Huang X, Zhang J, Huang Q, Zhang Z, Cao Y, Yang M, Li J, Li Z, Li C, Liu G, Zhong S, Feng G, Zhang M, Xiao Y, Lin K, Shen Y, Shao H, Shi Y, Yu X, Li X, Yao L, Du X, Xu Y, Kang P, Gao G, Ouyang B, Chen W, Zeng Z, Chen P, Chen C, Yang H. Effects of an Early Intensive Blood Pressure-lowering Strategy Using Remifentanil and Dexmedetomidine in Patients with Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Superiority, Randomized Controlled Trial. Anesthesiology. 2024 Jul 1;141(1):100-115. doi: 10.1097/ALN.0000000000004986.
- Li Q, Yakhkind A, Alexandrov AW, Alexandrov AV, Anderson CS, Dowlatshahi D, Frontera JA, Hemphill JC, Ganti L, Kellner C, May C, Morotti A, Parry-Jones A, Sheth KN, Steiner T, Ziai W, Goldstein JN, Mayer SA. Code ICH: A Call to Action. Stroke. 2024 Feb;55(2):494-505. doi: 10.1161/STROKEAHA.123.043033. Epub 2023 Dec 15.
- Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004 Jun;35(6):1364-7. doi: 10.1161/01.STR.0000128795.38283.4b. Epub 2004 Apr 29.
- Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens. 2005 Jun;23(6):1217-23. doi: 10.1097/01.hjh.0000170385.76826.4a.
- Zhang Y, Reilly KH, Tong W, Xu T, Chen J, Bazzano LA, Qiao D, Ju Z, Chen CS, He J. Blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China. J Hypertens. 2008 Jul;26(7):1446-52. doi: 10.1097/HJH.0b013e328300a24a.
- Leasure AC, Qureshi AI, Murthy SB, Kamel H, Goldstein JN, Woo D, Ziai WC, Hanley DF, Al-Shahi Salman R, Matouk CC, Sansing LH, Sheth KN, Falcone GJ. Association of Intensive Blood Pressure Reduction With Risk of Hematoma Expansion in Patients With Deep Intracerebral Hemorrhage. JAMA Neurol. 2019 Aug 1;76(8):949-955. doi: 10.1001/jamaneurol.2019.1141.
- Bako AT, Pan A, Potter T, Tannous J, Johnson C, Baig E, Meeks J, Woo D, Vahidy FS. Contemporary Trends in the Nationwide Incidence of Primary Intracerebral Hemorrhage. Stroke. 2022 Mar;53(3):e70-e74. doi: 10.1161/STROKEAHA.121.037332. Epub 2022 Feb 3.
- An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017 Jan;19(1):3-10. doi: 10.5853/jos.2016.00864. Epub 2017 Jan 31.
- Parry-Jones AR, Krishnamurthi R, Ziai WC, Shoamanesh A, Wu S, Martins SO, Anderson CS. World Stroke Organization (WSO): Global intracerebral hemorrhage factsheet 2025. Int J Stroke. 2025 Feb;20(2):145-150. doi: 10.1177/17474930241307876. Epub 2025 Jan 6.
- Steiner T, Purrucker JC, Aguiar de Sousa D, Apostolaki-Hansson T, Beck J, Christensen H, Cordonnier C, Downer MB, Eilertsen H, Gartly R, Gerner ST, Ho L, Holt Jahr S, Klijn CJ, Martinez-Majander N, Orav K, Petersson J, Raabe A, Sandset EC, Schreuder FH, Seiffge D, Al-Shahi Salman R. European Stroke Organisation (ESO) and European Association of Neurosurgical Societies (EANS) guideline on stroke due to spontaneous intracerebral haemorrhage. Eur Stroke J. 2025 Dec;10(4):1007-1086. doi: 10.1177/23969873251340815. Epub 2025 May 22.
- Qureshi AI, Qureshi MH. Acute hypertensive response in patients with intracerebral hemorrhage pathophysiology and treatment. J Cereb Blood Flow Metab. 2018 Sep;38(9):1551-1563. doi: 10.1177/0271678X17725431. Epub 2017 Aug 16.
- Sheth KN. Spontaneous Intracerebral Hemorrhage. N Engl J Med. 2022 Oct 27;387(17):1589-1596. doi: 10.1056/NEJMra2201449. No abstract available.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
31 juli 2026
Primärt slutförande (Beräknad)
1 oktober 2028
Avslutad studie (Beräknad)
31 december 2028
Studieregistreringsdatum
Först inskickad
28 juni 2026
Först inskickad som uppfyllde QC-kriterierna
5 juli 2026
Första postat (Faktisk)
10 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
10 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
5 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Cerebrovaskulära störningar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Patologiska processer
- Blödning
- Intrakraniella blödningar
- Patologiska tillstånd, tecken och symtom
- Hjärnblödning
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Azoler
- Syror, acykliska
- Karboxylsyror
- Imidazoler
- Piperidiner
- Propionates
- Remifentanil
- Dexmedetomidin
Andra studie-ID-nummer
- 2026SMU017
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
This study plans to make study protocol available to individuals or institutions in need after the completion of participant enrollment and data collation.
Such requests can be made by contacting the principal investigator.
Tidsram för IPD-delning
It is expected to be made available in June 2029 and will remain accessible for a period of 5 years.
Kriterier för IPD Sharing Access
Contacte to principal investigator.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .